<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00931463</url>
  </required_header>
  <id_info>
    <org_study_id>SECOND-LINE</org_study_id>
    <nct_id>NCT00931463</nct_id>
  </id_info>
  <brief_title>A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen</brief_title>
  <acronym>SECOND-LINE</acronym>
  <official_title>A Randomised Open-label Study Comparing the Safety and Efficacy of Ritonavir Boosted Lopinavir and 2-3N(t)RTI Backbone Versus Ritonavir Boosted Lopinavir and Raltegravir in Participants Virologically Failing First-line NNRTI/2N(t)RTI Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>amfAR, The Foundation for AIDS Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kirby Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that following virological failure of a standard NNRTI+2N(T)RTI
      regimen second-line antiretroviral therapy consisting of ritonavir-boosted lopinavir and
      2N(T)RTIs will offer comparable efficacy to that provided by ritonavir-boosted lopinavir and
      raltegravir.

      The study will be conducted for 96-weeks with the primary endpoint analyzed after 48-weeks.

      The primary endpoint is virological: a comparison of virological suppression in plasma &lt; 200
      copies/mL between the randomized arms after 48 weeks.

      Secondary and exploratory endpoints include virological, immunological, safety, clinical,
      metabolic, drug adherence, drug resistance and quality of life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In HIV-infected subjects who have virologically failed first-line antiretroviral therapy
      comprising 2N(t)RTI + NNRTI a regimen of second-line therapy incorporating ritonavir-boosted
      lopinavir and raltegravir provides comparable (i.e., non-inferior) antiretroviral efficacy
      over 48 weeks to a regimen containing ritonavir-boosted lopinavir and 2-3N(t)RTIs.

      Eligible patients will be randomised to one of two arms:

      I. ritonavir boosted lopinavir (LPV/r) 200mg/50mg 4 tabs once daily or 2 tabs twice daily +
      2-3N(t)RTIs

      II. ritonavir boosted lopinavir (LPV/r) 200mg/50mg 4 tabs once daily or 2 tabs twice daily +
      raltegravir 400 mg twice daily

      The primary objective of this study is to compare the virological efficacy of the two
      strategies as measured by the proportion of participants with HIV RNA &lt; 200 copies/mL 48
      weeks after randomisation.

      Secondary objectives include virological, immunological, safety and antiretroviral therapy
      endpoints.

      Exploratory endpoints include clinical, metabolic, drug resistance, medication adherence and
      quality of life endpoints.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants With Plasma HIV RNA &lt; 200 Copies/mL 48 Weeks After Randomization</measure>
    <time_frame>48 weeks following randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants With Plasma HIV RNA &lt; 200 Copies/mL 48 Weeks After Randomization, Per-protocol Population</measure>
    <time_frame>48 weeks</time_frame>
    <description>The per- protocol population includes those participants who fulfil the protocol in the terms of the eligibility, interventions, and outcome assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Plasma HIV RNA &lt; 200 Copies/mL 48 Weeks After Randomization, Per-protocol Population, Non-completer Classed as Failure</measure>
    <time_frame>48 weeks</time_frame>
    <description>The non-completer classed as failure analysis will include all randomised participants; participants who meet the following criteria will be defined as failures:
i. week 48 HIV RNA being above each threshold ii. has missing HIV-1 RNA data for any reason iii. stops randomly assigned therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Plasma HIV RNA &lt; 200 Copies/mL 48 Weeks After Randomization, Per-protocol Population, Baseline VL &gt;100,000 Copies Per mL</measure>
    <time_frame>48 weeks</time_frame>
    <description>The difference between treatment arms in proportion of participants with plasma HIV RNA &lt; 200 copies/mL 48 weeks after randomization, per-protocol population: stratified analysis by baseline plasma viral load (less than or equal to 100,000 copies per mL or &gt;100,000 copies per mL) on those participants who fulfil the protocol in the terms of the eligibility, interventions, and outcome assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Plasma HIV RNA &lt; 200 Copies/mL 48 Weeks After Randomization, Per-protocol Population, VL Less Than or Equal to 100,000 Copies Per mL</measure>
    <time_frame>48 weeks</time_frame>
    <description>The per- protocol population includes those participants who fulfil the protocol in the terms of the eligibility, interventions, and outcome assessment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">558</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Ritonavir-boosted lopinavir and 2N(t)RTI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This is the current standard of care for second line therapy following failure of standard first-line NNRTI+2N(t)RTIs according to WHO guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ritonavir-boosted lopinavir and raltegravir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is an experimental arm which is likely to be fully active in the presence of N(t)RTI mutations and which preliminary evidence suggests should be potent and durable.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>raltegravir</intervention_name>
    <description>400 mg raltegravir tablet taken every 12 hours</description>
    <arm_group_label>Ritonavir-boosted lopinavir and raltegravir</arm_group_label>
    <other_name>Isentress</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2N(t)RTI</intervention_name>
    <description>2N(t)RTIs as prescribed</description>
    <arm_group_label>Ritonavir-boosted lopinavir and 2N(t)RTI</arm_group_label>
    <other_name>nucleosides, nucleotides, nuncleoside backbone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir-boosted lopinavir</intervention_name>
    <description>2 heat-stable tablets of ritonavir-boosted lopinavir taken every 12 hours</description>
    <arm_group_label>Ritonavir-boosted lopinavir and 2N(t)RTI</arm_group_label>
    <arm_group_label>Ritonavir-boosted lopinavir and raltegravir</arm_group_label>
    <other_name>Aluvia, Kaletra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV-1 positive by licensed diagnostic test

          2. Aged 16 years or older (or minimum age as determined by local regulations or as legal
             requirements dictate)

          3. Have received first antiretroviral regimen consisting of an NNRTI plus 2N(t)RTIs for
             at least 24 weeks

          4. No change in antiretroviral therapy within 12 weeks prior to screening

          5. Failed first-line NNRTI + 2N(t)RTI combination therapy according to virological
             criteria defined by two consecutive (at least 7 days apart) HIV RNA results of greater
             then 500 copies/mL

          6. No prior or current exposure to HIV protease inhibitors and/or HIV integrase
             inhibitors

          7. Able to provide written informed consent

        Exclusion Criteria:

          1. The following laboratory variables:

               -  absolute neutrophil count (ANC) &lt; 500 cells/microlitres

               -  hemoglobin &lt; 7.0 g/decilitres

               -  platelet count &lt; 50,000 cells/microlitres

               -  ALT great than 5 x ULN

          2. Pregnant or nursing mothers

          3. Participants with active viral hepatitis B infection defined by the presence in serum
             of hepatitis B surface antigen

          4. Use of immunomodulators within 30 days prior to screening

          5. Use of any prohibited medications (rifampicin, midazolam, triazolam, cisapride,
             pimozide, amiodarone, dihydroergotamine, ergotamine, ergonovine, methylergonovine,
             astemizole, terfenadine, vardenafil, and St. John's wort)

          6. Intercurrent illness requiring hospitalization

          7. Active opportunistic disease not under adequate control in the opinion of the site
             Principal Investigator

          8. Participants with current alcohol or illicit substance abuse that in the opinion of
             the site Principal Investigator might adversely affect participation in the study

          9. Participants deemed by the site Principal Investigator unlikely to be able to remain
             in follow-up for the protocol-defined period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David A Cooper, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Kirby Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brian Gazzard, MD</last_name>
    <role>Study Chair</role>
    <affiliation>St. Stephen's Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Interzonal General de Agudos, Oscar Alende</name>
      <address>
        <city>Buenos Aires</city>
        <state>Mar del Plata Provincia</state>
        <zip>1900</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAICI</name>
      <address>
        <city>Buenos Aires</city>
        <state>Rosario Provincia de Sante Fe</state>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Agudos 'Teodoro Alvarez'</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1406</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FUNCEI</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Infecciosas FJ Muniz</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital J.M. Ramos Mejia</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Prof. Alejandro Posadas</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Rawson</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Central</name>
      <address>
        <city>Mendoza</city>
        <zip>5500</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albion Street Centre</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Clinic</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3182</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Universidad Catolica Pontificia</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Borja-Arriaran</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Group Practice</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J W Goethe Universitat</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Hong Kong</city>
        <state>Kowloon</state>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>YRG Care</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Infectious Diseases</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae-Dublin</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pelau Pinang</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sungai Buloh</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Malaysia</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Leon</name>
      <address>
        <city>Leon</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Medicas y Nutricion &quot;Salvado Zubiran&quot;</name>
      <address>
        <city>Mexico D.F.</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland Hospital</name>
      <address>
        <city>Grafton</city>
        <state>Auckland</state>
        <zip>1</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangel Hospital (ECWA)</name>
      <address>
        <city>Jos</city>
        <state>Plateau State</state>
        <country>Nigeria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jos University Teaching Hospital (JUTH)</name>
      <address>
        <city>Jos</city>
        <state>Plateau State</state>
        <country>Nigeria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Plateau State Specialist Hospital</name>
      <address>
        <city>Jos</city>
        <state>Plateau State</state>
        <country>Nigeria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Almenara</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMPACTA/Hospital Dos de Mayo</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Via Libre</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tan Tock Seng Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Josha Research</name>
      <address>
        <city>Bloemfontein</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desmond Tutu HIV Foundation</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chris Hani Baragwanath Hospital</name>
      <address>
        <city>Soweto</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chelsea and Westminster Hospital</name>
      <address>
        <city>Fulham</city>
        <state>London</state>
        <zip>SW10 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Chile</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>India</country>
    <country>Ireland</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Nigeria</country>
    <country>Peru</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>China</country>
    <country>Vietnam</country>
  </removed_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 1, 2009</study_first_submitted>
  <study_first_submitted_qc>July 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2009</study_first_posted>
  <results_first_submitted>October 14, 2013</results_first_submitted>
  <results_first_submitted_qc>December 1, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 17, 2014</results_first_posted>
  <last_update_submitted>February 12, 2014</last_update_submitted>
  <last_update_submitted_qc>February 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>second line therapy</keyword>
  <keyword>combination antiretroviral therapy</keyword>
  <keyword>first-line failure</keyword>
  <keyword>AIDS</keyword>
  <keyword>treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment took place from Mar-2010 till Sept-2011 at 37 sites in Argentina, Australia, Chile, UK, France, Hong Kong, India, Israel, Malaysia, Mexico, Peru, Nigeria, Singapore, South Africa, and Thailand. The sites had to be clinical facilities with a cohort of suitable patients and able to do protocol-mandated procedures.</recruitment_details>
      <pre_assignment_details>558 participants were enrolled in the study. 14 were excluded because of unverifiable data at one site and 3 dropped out before analysis, never received study treatment</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ritonavir-boosted Lopinavir and 2N(t)RTI</title>
          <description>This is the current standard of care for second line therapy following failure of standard first-line NNRTI+2N(t)RTIs according to WHO guidelines.</description>
        </group>
        <group group_id="P2">
          <title>Ritonavir-boosted Lopinavir and Raltegravir</title>
          <description>This is an experimental arm which is likely to be fully active in the presence of N(t)RTI mutations and which preliminary evidence suggests should be potent and durable.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="271"/>
                <participants group_id="P2" count="270"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="254"/>
                <participants group_id="P2" count="265"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ritonavir-boosted Lopinavir and 2N(t)RTI</title>
          <description>Lopinavir / ritonavir + 2-3N(t)RTI: LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily + 2-3 N(t)RTI</description>
        </group>
        <group group_id="B2">
          <title>Ritonavir-boosted Lopinavir and Raltegravir</title>
          <description>Lopinavir /ritonavir + raltegravir: LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily + raltegravir 400mg 1 tablet twice daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="271"/>
            <count group_id="B2" value="270"/>
            <count group_id="B3" value="541"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39" spread="8.81"/>
                    <measurement group_id="B2" value="38.55" spread="8.84"/>
                    <measurement group_id="B3" value="38.78" spread="8.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="128"/>
                    <measurement group_id="B3" value="243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="156"/>
                    <measurement group_id="B2" value="142"/>
                    <measurement group_id="B3" value="298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Southeast Asia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participants With Plasma HIV RNA &lt; 200 Copies/mL 48 Weeks After Randomization</title>
        <time_frame>48 weeks following randomization</time_frame>
        <population>modified intention-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Ritonavir-boosted Lopinavir and 2N(t)RTI</title>
            <description>This is the current standard of care for second line therapy following failure of standard first-line NNRTI+2N(t)RTIs according to WHO guidelines.</description>
          </group>
          <group group_id="O2">
            <title>Ritonavir-boosted Lopinavir and Raltegravir</title>
            <description>This is an experimental arm which is likely to be fully active in the presence of N(t)RTI mutations and which preliminary evidence suggests should be potent and durable.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Plasma HIV RNA &lt; 200 Copies/mL 48 Weeks After Randomization</title>
          <population>modified intention-to-treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="271"/>
                <count group_id="O2" value="270"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219"/>
                    <measurement group_id="O2" value="223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Plasma HIV RNA &lt; 200 Copies/mL 48 Weeks After Randomization, Per-protocol Population</title>
        <description>The per- protocol population includes those participants who fulfil the protocol in the terms of the eligibility, interventions, and outcome assessment</description>
        <time_frame>48 weeks</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Ritonavir-boosted Lopinavir and 2N(t)RTI</title>
            <description>This is the current standard of care for second line therapy following failure of standard first-line NNRTI+2N(t)RTIs according to WHO guidelines.</description>
          </group>
          <group group_id="O2">
            <title>Ritonavir-boosted Lopinavir and Raltegravir</title>
            <description>This is an experimental arm which is likely to be fully active in the presence of N(t)RTI mutations and which preliminary evidence suggests should be potent and durable.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Plasma HIV RNA &lt; 200 Copies/mL 48 Weeks After Randomization, Per-protocol Population</title>
          <description>The per- protocol population includes those participants who fulfil the protocol in the terms of the eligibility, interventions, and outcome assessment</description>
          <population>Per protocol</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="246"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="211"/>
                    <measurement group_id="O2" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Plasma HIV RNA &lt; 200 Copies/mL 48 Weeks After Randomization, Per-protocol Population, Non-completer Classed as Failure</title>
        <description>The non-completer classed as failure analysis will include all randomised participants; participants who meet the following criteria will be defined as failures:
i. week 48 HIV RNA being above each threshold ii. has missing HIV-1 RNA data for any reason iii. stops randomly assigned therapy</description>
        <time_frame>48 weeks</time_frame>
        <population>Non-completer classes as failure</population>
        <group_list>
          <group group_id="O1">
            <title>Ritonavir-boosted Lopinavir and 2N(t)RTI</title>
            <description>This is the current standard of care for second line therapy following failure of standard first-line NNRTI+2N(t)RTIs according to WHO guidelines.</description>
          </group>
          <group group_id="O2">
            <title>Ritonavir-boosted Lopinavir and Raltegravir</title>
            <description>This is an experimental arm which is likely to be fully active in the presence of N(t)RTI mutations and which preliminary evidence suggests should be potent and durable.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Plasma HIV RNA &lt; 200 Copies/mL 48 Weeks After Randomization, Per-protocol Population, Non-completer Classed as Failure</title>
          <description>The non-completer classed as failure analysis will include all randomised participants; participants who meet the following criteria will be defined as failures:
i. week 48 HIV RNA being above each threshold ii. has missing HIV-1 RNA data for any reason iii. stops randomly assigned therapy</description>
          <population>Non-completer classes as failure</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="271"/>
                <count group_id="O2" value="270"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208"/>
                    <measurement group_id="O2" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Plasma HIV RNA &lt; 200 Copies/mL 48 Weeks After Randomization, Per-protocol Population, Baseline VL &gt;100,000 Copies Per mL</title>
        <description>The difference between treatment arms in proportion of participants with plasma HIV RNA &lt; 200 copies/mL 48 weeks after randomization, per-protocol population: stratified analysis by baseline plasma viral load (less than or equal to 100,000 copies per mL or &gt;100,000 copies per mL) on those participants who fulfil the protocol in the terms of the eligibility, interventions, and outcome assessment</description>
        <time_frame>48 weeks</time_frame>
        <population>Baseline viral load &gt;100,000 copies per mL</population>
        <group_list>
          <group group_id="O1">
            <title>Ritonavir-boosted Lopinavir and 2N(t)RTI</title>
            <description>This is the current standard of care for second line therapy following failure of standard first-line NNRTI+2N(t)RTIs according to WHO guidelines.</description>
          </group>
          <group group_id="O2">
            <title>Ritonavir-boosted Lopinavir and Raltegravir</title>
            <description>This is an experimental arm which is likely to be fully active in the presence of N(t)RTI mutations and which preliminary evidence suggests should be potent and durable.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Plasma HIV RNA &lt; 200 Copies/mL 48 Weeks After Randomization, Per-protocol Population, Baseline VL &gt;100,000 Copies Per mL</title>
          <description>The difference between treatment arms in proportion of participants with plasma HIV RNA &lt; 200 copies/mL 48 weeks after randomization, per-protocol population: stratified analysis by baseline plasma viral load (less than or equal to 100,000 copies per mL or &gt;100,000 copies per mL) on those participants who fulfil the protocol in the terms of the eligibility, interventions, and outcome assessment</description>
          <population>Baseline viral load &gt;100,000 copies per mL</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Plasma HIV RNA &lt; 200 Copies/mL 48 Weeks After Randomization, Per-protocol Population, VL Less Than or Equal to 100,000 Copies Per mL</title>
        <description>The per- protocol population includes those participants who fulfil the protocol in the terms of the eligibility, interventions, and outcome assessment</description>
        <time_frame>48 weeks</time_frame>
        <population>Baseline viral load &lt;=100,000 copies per mL</population>
        <group_list>
          <group group_id="O1">
            <title>Ritonavir-boosted Lopinavir and 2N(t)RTI</title>
            <description>This is the current standard of care for second line therapy following failure of standard first-line NNRTI+2N(t)RTIs according to WHO guidelines.</description>
          </group>
          <group group_id="O2">
            <title>Ritonavir-boosted Lopinavir and Raltegravir</title>
            <description>This is an experimental arm which is likely to be fully active in the presence of N(t)RTI mutations and which preliminary evidence suggests should be potent and durable.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Plasma HIV RNA &lt; 200 Copies/mL 48 Weeks After Randomization, Per-protocol Population, VL Less Than or Equal to 100,000 Copies Per mL</title>
          <description>The per- protocol population includes those participants who fulfil the protocol in the terms of the eligibility, interventions, and outcome assessment</description>
          <population>Baseline viral load &lt;=100,000 copies per mL</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188"/>
                    <measurement group_id="O2" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>96 weeks</time_frame>
      <desc>AEs reported by investigators</desc>
      <group_list>
        <group group_id="E1">
          <title>Ritonavir-boosted Lopinavir and 2N(t)RTI</title>
          <description>This is the current standard of care for second line therapy following failure of standard first-line NNRTI+2N(t)RTIs according to WHO guidelines.</description>
        </group>
        <group group_id="E2">
          <title>Ritonavir-boosted Lopinavir and Raltegravir</title>
          <description>This is an experimental arm which is likely to be fully active in the presence of N(t)RTI mutations and which preliminary evidence suggests should be potent and durable.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Death - unknown, possible due to recurrent anaemia, HIV disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Fever and anaemia hospitalization</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Haematoma inside lower colon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Hemoptysis, resulted in death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Abdominal Pain- death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Dysentery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Gangrenous bowel</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Acute abdomen</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Diarrhoea for over consumption of alcohol</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Bloody diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Death, cause unknown</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Death, probably due to myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Tension Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>CMV Retinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Cryptococcal meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Cryptococcal disseminated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Extrapulmonary TB - resulted in death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Giardiasis and nocardiasis resulting in death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>HSV meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>herpez zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Varizella zoster infection and MSSA cervical lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Plasmodiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Skin ulcers superinfected</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>TB meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Varizella zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Viral infection (presumptive)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Cerebral toxoplasmosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Crytococcal meningitis and giardiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Infective diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>miliary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Perianal HSV ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>pneumocystis jirovecii pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>probable PCP and presumptive mycobacterium TB</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Salmonella and PCP</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Car accident - resulted in death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Contusions resulting in hospitalisations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Fracture of right ankle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Supra Condylar fracture of right femur</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>CIN II</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Cervical cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>kaposi sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Probable righ ovarian carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the anal canal - resulted in death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Asymptomatic neuro-syphillis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>miscarriage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Gestational diabetes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Renal failure resulted in death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Acute renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Genital bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Asthma Attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Lung abscess resulted in death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Right middle lobe pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Right side pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Delirium, secondary alcohol withdrawal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Skin graft detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="243" subjects_at_risk="271"/>
                <counts group_id="E2" subjects_affected="232" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemias nonhaemolytic and marrow depression</sub_title>
                <counts group_id="E1" events="21" subjects_affected="10" subjects_at_risk="271"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Decreased and nonspecific blood pressure disorders and shock</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="271"/>
                <counts group_id="E2" events="17" subjects_affected="15" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Lipid metabolism disorders</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="271"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular infections, irritations and inflammations</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="271"/>
                <counts group_id="E2" events="22" subjects_affected="17" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal inflammatory conditions</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="271"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Gastrointestinal motility and defaecation conditions</sub_title>
                <counts group_id="E1" events="177" subjects_affected="128" subjects_at_risk="271"/>
                <counts group_id="E2" events="131" subjects_affected="102" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Gastrointestinal signs and symptoms</sub_title>
                <counts group_id="E1" events="145" subjects_affected="72" subjects_at_risk="271"/>
                <counts group_id="E2" events="82" subjects_affected="51" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic conditions</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="271"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Body temperature conditions</sub_title>
                <counts group_id="E1" events="32" subjects_affected="26" subjects_at_risk="271"/>
                <counts group_id="E2" events="26" subjects_affected="23" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Dental and gingival conditions</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="271"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>General system disorders NEC</sub_title>
                <counts group_id="E1" events="47" subjects_affected="34" subjects_at_risk="271"/>
                <counts group_id="E2" events="41" subjects_affected="33" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Headaches</sub_title>
                <counts group_id="E1" events="52" subjects_affected="41" subjects_at_risk="271"/>
                <counts group_id="E2" events="36" subjects_affected="30" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Sleep disorders and disturbances</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="271"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic and hepatobiliary disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="271"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial infectious disorders</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="271"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Fungal infectious disorders</sub_title>
                <counts group_id="E1" events="39" subjects_affected="33" subjects_at_risk="271"/>
                <counts group_id="E2" events="54" subjects_affected="47" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Infections - pathogen class unspecified</sub_title>
                <counts group_id="E1" events="188" subjects_affected="103" subjects_at_risk="271"/>
                <counts group_id="E2" events="243" subjects_affected="124" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Protozoal infectious disorders</sub_title>
                <counts group_id="E1" events="40" subjects_affected="21" subjects_at_risk="271"/>
                <counts group_id="E2" events="30" subjects_affected="13" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Viral infectious disorders</sub_title>
                <counts group_id="E1" events="53" subjects_affected="40" subjects_at_risk="271"/>
                <counts group_id="E2" events="56" subjects_affected="41" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injuries NEC</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="271"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Appetite and general nutritional disorders</sub_title>
                <counts group_id="E1" events="33" subjects_affected="25" subjects_at_risk="271"/>
                <counts group_id="E2" events="16" subjects_affected="12" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Bone, calcium, magnesium and phosphorus metabolism disorders</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="271"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint disorders</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="271"/>
                <counts group_id="E2" events="23" subjects_affected="22" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Muscle disorders</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="271"/>
                <counts group_id="E2" events="23" subjects_affected="19" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders NEC</sub_title>
                <counts group_id="E1" events="51" subjects_affected="39" subjects_at_risk="271"/>
                <counts group_id="E2" events="53" subjects_affected="44" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurological disorders NEC</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="271"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy, labour, delivery and postpartum conditions</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="271"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal disorders (excl nephropathies)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="271"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Female reproductive tract infections and inflammations</sub_title>
                <counts group_id="E1" events="18" subjects_affected="14" subjects_at_risk="271"/>
                <counts group_id="E2" events="22" subjects_affected="15" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Menstrual cycle and uterine bleeding disorders</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="271"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Reproductive tract disorders NEC</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="271"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Vulvovaginal disorders (excl infections and inflammations)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="271"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory disorders NEC</sub_title>
                <counts group_id="E1" events="77" subjects_affected="51" subjects_at_risk="271"/>
                <counts group_id="E2" events="112" subjects_affected="58" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Epidermal and dermal conditions</sub_title>
                <counts group_id="E1" events="108" subjects_affected="66" subjects_at_risk="271"/>
                <counts group_id="E2" events="115" subjects_affected="66" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Oral soft tissue conditions</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="271"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Skin appendage conditions</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="271"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular haemorrhagic disorders</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="271"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>Vascular hypertensive disorders</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="271"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is a Clinical Trial Agreement signed with each PI detailing the publication policy and disclosure of study's information, in summary:
The Institution, its personnel and the Principal Investigator must not Publish or present any aspect of the Study without the prior written approval of the sponsor, except for the purposes of internal training
Publications or presentations of results from the Study will follow the agreement's publication/presentation guidelines</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof Sean Emery</name_or_title>
      <organization>The Kirby Institute</organization>
      <phone>+61293850900</phone>
      <email>semery@kirby.unsw.edu.au</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

